← Leaderboards
Debasish Tripathy
University Of California San Francisco
$1,350,639
Attributed
$1,350,639
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,350,639 · 2
By mechanism
P50$1,034,095 · 1
U54$316,544 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Katherine Kurshan Matthay$7,757,759
- Francis C Szoka$17,593,815
- Joe W. Gray$35,260,197
- John W Park$3,200,648
- Michael Shannon McGrath$55,606,332
Others in their field
Top investigators on “Breast Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$251,848,784
- Richard L Schilsky · University Of Chicago$110,812,897
- Walter John Curran · Thomas Jefferson University$96,881,565
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$87,504,493
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,613,341
Research focus
Breast NeoplasmsCancer Information SystemCancer Registry /ResourceHuman DataClinical TrialsBiomedical FacilityHuman SubjectHuman Therapy EvaluationLaboratory MouseMicroarray TechnologyMonoclonal AntibodyNeoplasm /Cancer ChemotherapyNeoplasm /Cancer DiagnosisNeoplasm /Cancer GeneticsNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer TherapyNonhuman Therapy EvaluationOncogenesOncoproteinsPatient Oriented ResearchAntineoplasticsReceptorAntireceptor AntibodyCombination Cancer Therapy
Grant awards (8)
EXPRESSION ANALYSIS OF ERBB RECEPTOR TARGETED THERAPIES$158,272
U54 · FY2006 · CA · contact PI
CORE--CLINICAL CORE$206,819
P50 · FY2002 · CA
CORE--CLINICAL CORE$206,819
P50 · FY2002 · CA
EXPRESSION ANALYSIS OF ERBB RECEPTOR TARGETED THERAPIES$158,272
U54 · FY2002 · CA
CORE--CLINICAL CORE$206,819
P50 · FY2001 · CA
CORE--CLINICAL CORE$206,819
P50 · FY2001 · CA
EXPRESSION ANALYSIS OF ERBB RECEPTOR TARGETED THERAPIES$0
U54 · FY2001 · CA
CORE--CLINICAL CORE$206,819
P50 · FY2000 · CA